We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New Quantitative Strategy for Pooling COVID-19 Tests Could Detect Outbreaks Early

By LabMedica International staff writers
Posted on 09 Mar 2021
Scientists have developed a new model to evaluate the performance of a group testing strategy for the SARS-CoV-2 virus, which involves pooling samples from multiple individuals in order to conduct a single RT-PCR test on the whole group.

The theoretical study by scientists at Université Grenoble Alpes (Grenoble, France) accounts for both dilution effect and the detection limits of the RT-PCR test, in an effort to assess the number of potential false negatives based on pooled sample size, to optimize group size thereby minimizing epidemic risk, and finally to more accurately determine the number of contaminated individuals within a given population.

The principle of group testing is simple mathematically speaking: rather than test one hundred samples (one per individual), they can be pooled into ten groups of ten, with only one test for each group. More...
If the test result for a group is positive, then at least one of the group’s samples contains the infectious agent. Conversely, a negative result should, in principle, indicate that none of the combined samples contains the infectious agent. Sample pooling method can reduce the cost can accelerate screening campaign, yet pooling can result in a false positive result whenever mixing samples involves a too large dilution - namely when the quantity of the virus in the tested sample falls below the test’s level of detection.

To assess the efficiency of screening based on a group testing strategy, the researchers who are members of the MODCOV19 platform have developed a mathematical model that estimates this dilution effect based on sample group size. Their model can quantify the reduction of sensitivity for tests, hence the capacity of tests with larger or smaller groups to detect the presence of a contagious individual. Unlike methods that try to minimize the number of tests needed to establish an individual diagnostic for the contaminated individual or individuals, the model’s central aim is to help optimize a collective screening strategy: how best to optimize group size in order to detect a maximum number of individuals all while limiting the risk of false negatives?

The researchers also present an accurate method for measuring the proportion of individuals infected in the tested population (known as prevalence) which can guide the application of preventive measures against epidemic risk. According to their study, group testing is of particular interest because it can quickly and regularly evaluate the presence of SARS-COV-2 within “closed” communities (such as nursing homes or university residences).

Related Links:
Université Grenoble Alpes


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.